The AI in antibody discovery market size was valued at USD 546.17 million in 2025 and is projected to grow from USD 662.99 million in 2026 to USD 3,162.19 million by 2034, registering a CAGR of 21.57% during the forecast period (2026–2034). North America dominated the AI in antibody discovery market with a market share of 43.72% in 2025.
AI in antibody discovery refers to the application of artificial intelligence technologies, including machine learning, deep learning, and generative AI, to accelerate the discovery, design, and optimization of therapeutic antibodies. These platforms analyze biological and molecular data to predict antibody-antigen interactions, improve binding affinity, and support candidate selection. They are widely used in oncology, autoimmune diseases, infectious diseases, and rare disease research to enhance biologics development.
The AI in antibody discovery market demand is driven by the rising biologics research, growing AI adoption in drug discovery, and the need for faster therapeutic development. Continuous technological advancements, expanding strategic collaborations, and increasing precision medicine initiatives are contributing to AI in antibody discovery market growth.
Download a Free Sample to Explore Detailed Market Insights
The market is witnessing a shift from conventional antibody screening toward generative AI models capable of designing novel antibody sequences with desired properties. Instead of relying solely on existing antibody libraries, researchers are using AI to generate candidates with improved affinity, specificity, and developability. This transition is accelerating early-stage discovery while reducing experimental iterations and development timelines. For example, Generate:Biomedicines uses generative AI models to design therapeutic proteins and antibody candidates for multiple disease indications.
Another significant trend is the integration of protein language models into antibody discovery workflows to better predict protein structure, antigen binding, and sequence functionality. These AI models learn from extensive biological sequence databases, enabling faster identification and optimization of promising therapeutic antibodies. The transition toward data-driven molecular design is improving prediction accuracy and research efficiency across biologics development. For example, Absci leverages AI-driven protein design and predictive modeling to accelerate antibody discovery and engineering.
The AI in the antibody discovery market forecasts continued investment activity driven by increasing adoption of AI across biologics research, growing demand for faster therapeutic antibody development, and expanding collaborations between biotechnology companies and technology investors. Investors are prioritizing companies developing generative AI platforms and computational antibody engineering technologies. Strategic funding is also supporting platform expansion and commercialization of an AI-enabled antibody discovery solution.
Key Investment and Funding Activities in AI in Antibody Discovery Market, 2025–2026
Generate Biomedicines
USD 400 million (IPO)
In February 2026, Generate Biomedicines raised through its Nasdaq IPO. The proceeds will support advancement of its AI enabled biologics and antibody pipeline and continued expansion of its generative AI drug discovery platform
Chai Discovery
USD 130 million (Series B)
In December 2025, Chai Discovery secured financing led by General Catalyst and Oak HC/FT. The funding supports expansion of its AI platform for antibody and molecular design, commercialization, and research infrastructure.
Increasing Adoption of AI-powered Drug Discovery Platforms and Rising Demand for Therapeutic Antibodies Drives Market
The growing adoption of artificial intelligence across pharmaceutical research is driving demand for AI in antibody discovery by enabling faster identification and optimization of therapeutic antibody candidates. AI platforms reduce experimental screening efforts, improve prediction accuracy, and shorten discovery timelines, making antibody development more efficient. For instance, AstraZeneca partnered with Absci to leverage generative AI for the discovery and development of therapeutic antibodies against oncology targets. Such collaborations improve research productivity, reduce development costs, and accelerate biologics pipelines, thereby increasing demand for AI-enabled antibody discovery platforms.
The increasing prevalence of cancer, autoimmune disorders, infectious diseases, and rare diseases is driving demand for therapeutic antibodies, creating the need for faster and more efficient discovery platforms. Conventional antibody discovery methods are resource-intensive and time-consuming, prompting pharmaceutical and biotechnology companies to adopt AI technologies that accelerate candidate identification, optimization, and validation. This improves research efficiency, supports expanding biologics pipelines, and enables faster development of innovative antibody therapeutics across multiple disease areas.
Limited Availability of High-quality Biological Data and High Implementation Costs Restrain Market Expansion
AI models rely on large volumes of high-quality, annotated biological and clinical datasets to accurately predict antibody structures and antigen interactions. However, fragmented databases, inconsistent data formats, limited access to proprietary datasets, and variability in experimental results reduce model reliability and predictive accuracy. These challenges restrict the development and validation of robust AI models, slowing adoption among pharmaceutical and biotechnology companies and limiting broader commercialization of AI-enabled antibody discovery platforms.
Deploying AI platforms for antibody discovery requires significant investment in computational infrastructure, specialized software, skilled AI professionals, and integration with laboratory workflows. In addition, AI-generated antibody candidates must undergo extensive experimental validation, regulatory assessment, and preclinical testing before clinical development, increasing both time and costs. These financial and technical barriers limit adoption, particularly among small biotechnology companies and academic research organizations with constrained research budgets.
Growth of Multispecific & Next Generation Antibody Development and Increasing Adoption of In Silico Antibody Developability Assessment Open New Revenue Avenues
The increasing focus on bispecific antibodies, antibody drug conjugates, and multispecific biologics is creating significant opportunities for AI-enabled antibody discovery platforms. These complex molecules require extensive sequence optimization, structural prediction, and binding analysis, making AI an essential tool for accelerating design and reducing development risks. For example, BigHat Biosciences utilizes its AI-driven Milliner platform to engineer next-generation antibody therapeutics with improved functionality and developability.
The increasing use of AI for early-stage developability assessment presents a major opportunity for market players. AI models can predict antibody stability, aggregation propensity, immunogenicity, manufacturability, and formulation characteristics before laboratory validation. This enables pharmaceutical companies to eliminate poor candidates earlier, reduce costly failures, improve development efficiency, and accelerate the progression of therapeutic antibodies into preclinical and clinical development.
Need to Maintain Consistent Clinical Reliability and Complex Integration of AI Models with Proprietary Biological Data Challenges Market Growth
A major challenge for the market is establishing consistent confidence in AI-generated antibody candidates across diverse therapeutic targets. While AI can rapidly identify promising sequences, experimental validation remains essential to confirm efficacy, safety, and biological performance. Variability between computational predictions and laboratory outcomes often increases development timelines and costs, making pharmaceutical companies cautious about relying extensively on AI-driven antibody discovery.
Integrating AI platforms with proprietary biological datasets, laboratory information management systems, and existing drug discovery workflows remains a significant challenge. Differences in data formats, limited interoperability, fragmented databases, and strict data governance policies complicate seamless implementation. These technical barriers reduce workflow efficiency, delay AI model deployment, and require substantial investments in data harmonization, infrastructure modernization, and cross-functional expertise.
Based on offering, the software platforms segment dominates the market with a revenue share of 37.84%, owing to proprietary antibody foundation models, seamless integration with laboratory information management systems, and cloud-based computational workflows. These platforms enable rapid sequence analysis and collaborative biologics research.
The discovery services segment is expected to grow at a CAGR of around 21.79% during the forecast period due to increasing outsourcing of AI-assisted antibody discovery, limited in-house computational biology capabilities, and growing demand for integrated wet lab validation. Service providers offer antibody discovery solutions that reduce infrastructure investments and accelerate development timelines.
In 2025, structure prediction accounted for a share of 32.12% in the AI in antibody discovery market, due to its critical role in accurately modeling antibody antigen binding conformations, enabling rational molecular engineering, and improving candidate selection before laboratory validation. High prediction accuracy reduces experimental iterations while supporting efficient therapeutic antibody optimization.
The generative AI and protein language models segment is expected to grow at a CAGR of 22.33% during the forecast period, driven by de novo antibody sequence generation, biological sequence learning, and continuous self-improving molecular prediction capabilities. These technologies significantly expand therapeutic design possibilities, accelerating innovation in discovery.
By application, target identification & validation accounted for a share of 29.68% in 2025 due to AI-driven biomarker prioritization and efficient identification of disease-associated therapeutic targets. Early target validation improves downstream antibody discovery success while reducing costly research failures across biologics development.
The lead optimization & engineering segment is expected to grow at a CAGR of 22.50% during the forecast period, driven by computational affinity maturation, sequence liability prediction, and simultaneous optimization of stability and manufacturability. AI enables precise molecular refinement that improves therapeutic performance while minimizing laboratory redesign cycles.
By antibody modaility, monoclonal antibodies accounted for the largest market share of 54.41% in 2025, as they possess established clinical development pathways, abundant training datasets for AI model development, and widespread therapeutic applicability across multiple disease indications. Their extensive commercial success encourages continued AI-assisted optimization and discovery activities.
The antibody drug conjugate segment is expected to register a CAGR of 22.76% during the forecast period due to increasing computational optimization of linker chemistry, payload conjugation sites, and tumor targeting specificity. AI accelerates complex ADC design by simultaneously optimizing multiple molecular characteristics for therapeutic efficacy, driving segment growth.
The pharmaceutical companies segment accounted for a dominant share of 32.30% in 2025, owing to extensive biologic pipelines and strong capabilities for integrating computational discovery with clinical development. Large organizations increasingly deploy AI platforms to improve portfolio productivity and accelerate therapeutic innovation.
The CROs & CDMOs segment is projected to grow at a CAGR of 22.85% during the forecast timeframe, driven by contract organizations increasingly using AI-enabled antibody discovery within integrated research and development services. Growing demand for flexible outsourcing and specialized computational expertise also drive segment growth.
North America: Market Dominance Led by Strong AI Biotech Ecosystem and High Biopharmaceutical R&D Investments
The North America AI in antibody discovery market accounted for the largest regional share of 43.72% in 2025, driven by the presence of leading AI biotechnology companies, substantial pharmaceutical R&D investments, and rapid adoption of artificial intelligence across biologics discovery. The region benefits from advanced computational infrastructure, extensive biomedical datasets, and strong collaborations between technology developers and pharmaceutical companies. According to the Biotechnology Innovation Organization (BIO), the US remains the world's largest biotechnology market, supporting continuous innovation in AI-enabled therapeutic antibody discovery.
The US AI in antibody discovery market was valued at USD 208.70 million in 2025, driven by increasing investments in generative AI for biologics research, expanding collaborations between pharmaceutical companies and AI platform developers, and growing demand for accelerated antibody development. The country's robust biotechnology ecosystem, world-leading research universities, and concentration of AI-native drug discovery companies continue to strengthen innovation in computational antibody engineering. Strong venture capital funding and supportive commercialization environments further drive adoption of AI-enabled antibody discovery technologies.
The Canada AI in antibody discovery market size was valued at USD 30.09 million in 2025, supported by the country’s growing biotechnology ecosystem, increasing investments in AI-driven life science research, and collaborations between academic institutions and biotech companies. Canada’s strong AI research infrastructure, including the Vector Institute and Mila—Quebec AI Institute, supports the development of advanced machine learning applications.
Asia Pacific: Fastest Growth Driven by Increasing Biotechnology Investments and Rising AI Adoption in Pharmaceutical Research
The Asia Pacific AI in antibody discovery market is expected to grow at a CAGR of 23.26% during the forecast period, showcasing the fastest regional growth. Growth is supported by increasing biotechnology investments, expanding AI research infrastructure, rising biologics development activities, and growing adoption of computational antibody engineering platforms. The region benefits from large pharmaceutical manufacturing capabilities, increasing clinical research activities, growing availability of biological datasets, and government initiatives supporting artificial intelligence integration in healthcare and life science innovation.
The China AI in antibody discovery market size was valued at USD 30.71 million in 2025, supported by the expansion of biotechnology companies, increasing AI adoption in pharmaceutical research, and rising investments in antibody therapeutics development. The country has developed a strong ecosystem of AI-driven drug discovery companies, supported by large biomedical datasets and advanced computational capabilities. For example, XtalPi, a China-based AI pharmaceutical technology company, applies artificial intelligence and computational platforms to accelerate drug discovery and molecular design, including biologics research applications.
The India AI in antibody discovery market size was valued at USD 15.70 million in 2025, fueled by expanding biotechnology startups, increasing pharmaceutical outsourcing activities, and growing adoption of AI-based research tools. The country’s strong pharmaceutical manufacturing base and increasing investment in digital healthcare technologies are creating opportunities for biologics discovery. Increasing collaborations between academic institutions, AI companies, and biotech firms are strengthening adoption of AI-driven antibody discovery solutions.
The Japan AI in antibody discovery market was valued at USD 18.12 million in 2025, supported by advanced pharmaceutical R&D infrastructure, strong biologics research capabilities, and increasing adoption of artificial intelligence for antibody engineering and therapeutic discovery. Japan’s focus on precision medicine, availability of high-quality biomedical datasets, and integration of AI into life science research are accelerating computational drug development. The country’s growing partnerships between academia, technology firms, and pharmaceutical companies are further strengthening AI-supported antibody discovery adoption.
The AI in antibody discovery market competitive landscape is moderately fragmented, with competition driven by AI native biotechnology companies, computational drug discovery firms, and established pharmaceutical organizations integrating artificial intelligence into biologics research. Leading players compete through advanced machine learning algorithms, generative AI capabilities, proprietary biological datasets, and strategic collaborations with pharmaceutical companies to accelerate antibody development. The AI in antibody discovery market ecosystem is shaped by continuous advancements in computational biology, expanding cloud-based research infrastructure, increasing investment in AI-driven therapeutics, and evolving biologics pipelines.
September 2025: Absci announced a strategic collaboration with Oracle Cloud Infrastructure and AMD to accelerate generative AI-driven drug discovery.
August 2025: Absci and Almirall expanded their AI drug discovery collaboration by adding a second dermatology target after the successful delivery of AI-designed functional antibody candidates against the first target.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Pavan Warade is a Research Analyst with over 4 years of expertise in Technology and Aerospace & Defense markets. He delivers detailed market assessments, technology adoption studies, and strategic forecasts. Pavan’s work enables stakeholders to capitalize on innovation and stay competitive in high-tech and defense-related industries.
We are featured on:
sales@straitsresearch.com